Findings

What do systematic reviews say?

3,971 questions · 9,849 findings · 853 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,150 · 11.7%GRADE not reported 3,387 · 34.4%Very low 1,963 · 19.9%Low 1,809 · 18.4%Moderate 1,207 · 12.3%High 333 · 3.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ramosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Moderate

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosnetupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
High

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

Palonosetron (0 RCTs; 0 participants) · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

aprepitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

azasetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

aprepitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 7800 participants
Low